Nkarta Inc. (NKTX): Price and Financial Metrics


Nkarta Inc. (NKTX): $5.04

-0.03 (-0.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NKTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NKTX Stock Price Chart Interactive Chart >

Price chart for NKTX

NKTX Price/Volume Stats

Current price $5.04 52-week high $20.35
Prev. close $5.07 52-week low $4.83
Day low $5.03 Volume 296,000
Day high $5.20 Avg. volume 690,539
50-day MA $6.83 Dividend yield N/A
200-day MA $11.91 Market Cap 246.02M

Nkarta Inc. (NKTX) Company Bio


Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.


NKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

NKTX Latest Social Stream


Loading social stream, please wait...

View Full NKTX Social Stream

Latest NKTX News From Around the Web

Below are the latest news stories about NKARTA INC that investors may wish to consider to help them evaluate NKTX as an investment opportunity.

Nkarta promotes David Shook to Chief Medical Officer

  • Nkarta (NASDAQ:NKTX) notifies the promotion of David Shook, to the role of CMO.
  • Shook has expertise in cell therapy development and continues to lead Nkarta's global clinical development and regulatory operations.
  • Shook joined Nkarta in 2020 and was appointed as VP, clinical development in 2022.
...

Seeking Alpha | January 10, 2023

Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the developm

Yahoo | January 9, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today!

William White on InvestorPlace | December 5, 2022

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cyclesPatients with CR observed across multiple NHL histologies, including LBCLConsolidation dosing administered to 7 patients with CRs with aim to eradicate residual tumor cells and prolong responseDurable res

Yahoo | December 5, 2022

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ETSOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate. Conference Call and Webcast

Yahoo | December 2, 2022

Read More 'NKTX' Stories Here

NKTX Price Returns

1-mo -4.18%
3-mo -61.23%
6-mo -62.69%
1-year -43.62%
3-year N/A
5-year N/A
YTD -15.86%
2022 -60.98%
2021 -75.03%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6474 seconds.